文献速递淋巴瘤白血病

来那度胺治疗的慢性淋巴细胞白血病患者癌症基因突变的临床意义

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
PubMed 文献 · Blood · 2018-01-22

本研究对102例初治和186例复发/难治慢性淋巴细胞白血病患者进行295个癌症基因的靶向测序,这些患者均在本机构接受来那度胺为基础的治疗。最常见突变为SF3B1(15%)、NOTCH1(14%)和TP53(14%),复发/难治患者TP53突变显著多于初治患者。del(17p)、del(11q)、复杂核型及TP53、KRAS、DDX3X突变与较差的总缓解相关;复发/难治患者中SF3B1和MGA突变与较差的总缓解相关;del(17p)和TP53突变与较差的总生存和无进展生存相关。

要点

  • 来那度胺治疗的慢性淋巴细胞白血病患者中,SF3B1(15%)、NOTCH1(14%)、TP53(14%)是最常见突变。
  • del(17p)、del(11q)、复杂核型及TP53、KRAS、DDX3X突变与较差的总缓解相关。
  • 复发/难治患者中,复杂核型和SF3B1突变与较差的总生存和无进展生存相关。

核心结论

  • 慢性淋巴细胞白血病中的癌症基因突变有助于完善风险分层,并增加对预后和治疗反应的预测信息。

研究设计与样本

  • 对102例初治和186例复发/难治慢性淋巴细胞白血病患者的标本进行295个癌症基因的靶向捕获测序,患者均在本机构接受来那度胺为基础的治疗。

主要发现

  • 最常见突变为SF3B1(15%),其次为NOTCH1(14%)和TP53(14%),复发/难治患者TP53突变显著多于初治患者。
  • 所有来那度胺治疗患者中,del(17p)(P ≤ .001)、del(11q)(P = .032)、复杂核型(P = .022)及TP53(P ≤ .001)、KRAS(P = .034)、DDX3X(P ≤ .001)突变与较差的总缓解相关。
  • 复发/难治患者中,SF3B1和MGA突变与较差的总缓解相关(P = .025和.035)。
  • 初治和复发/难治患者中,del(17p)和TP53突变与较差的总生存和无进展生存相关。
  • 复发/难治患者中,复杂核型和SF3B1突变与较差的总生存和无进展生存相关;DDX3X突变仅与较差的无进展生存相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenalidomide is clinically active in chronic lymphocytic leukemia (CLL), but its effectiveness in the context of the CLL mutational landscape is unknown. We performed targeted capture sequencing of 295 cancer genes in specimens from 102 CLL patients with treatment-naïve disease (TN patients) and 186 CLL patients with relapsed/refractory disease (R/R patients) who received lenalidomide-based therapy at our institution. The most frequently mutated gene was SF3B1 (15%), followed by NOTCH1 (14%) and TP53 (14%), with R/R patients having significantly more TP53 mutations than did TN patients. Among all lenalidomide-treated patients, del(17p) (P ≤ .001), del(11q) (P = .032), and complex karyotype (P = .022), along with mutations in TP53 (P ≤ .001), KRAS (P = .034), and DDX3X (P ≤ .001), were associated with worse overall response (OR). R/R patients with SF3B1 and MGA mutations had significantly worse OR (P = .025 and .035, respectively). TN and R/R patients with del(17p) and TP53 mutations had worse overall survival (OS) and progression-free survival (PFS). In R/R patients, complex karyotype and SF3B1 mutations were associated with worse OS and PFS; DDX3X mutations were associated with worse PFS only. Weibull regression multivariate analysis revealed that TP53 aberrations (del(17p), TP53 mutation, or both), along with complex karyotype and SF3B1 mutations, were associated with worse OS in the R/R cohort. Taken together, cancer gene mutations in CLL contribute to the already comprehensive risk stratification and add to prognosis and response to treatment. The related trials were registered at www.clinicaltrials.gov as #NCT00267059, #NCT00535873, #NCT00759603, #NCT01446133, and #NCT01002755.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Takahashi K, Hu B, Wang F, et al. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018. PMID: 29358183. doi:10.1182/blood-2017-11-817296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。